CinCor Pharma, Inc.
CinCor Pharma, Inc.（CINC）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · CINC · 截至 2026年6月9日
活动摘要
买入笔数
6
P-Purchase only
卖出笔数
2
近12个月
买卖比
3.00
Buy/Sell (by trades)
整体情绪
CinCor Pharma, Inc.内部人在过去近12个月净买入股份，可能反映对公司前景的信心。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
CINC 季度内部人买卖趋势
CINC 内幕交易卖出 · CINC 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
近期内幕交易记录
CINC 高管卖出股份 · CINC 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Feb 24, 2023 | 5AM Partners VI, LLC 10 percent owner | Other | 496,323 | $12.90M⚡ | Form 4 |
| Feb 24, 2023 | HEALY JAMES Director | Other | 9,803 | $255K | Form 4 |
| Feb 24, 2023 | HEALY JAMES Director | Other | 19,608 | — | Form 4 |
| Nov 28, 2022 | HEALY JAMES Director | Sale | 6,000 | $86K | Form 4 |
| Feb 24, 2023 | HEALY JAMES Director | Other | 6,073,949 | $157.92M⚡ | Form 4 |
| Feb 24, 2023 | Freeman Mason Chief Medical Officer | Other | 2,494 | $65K | Form 4 |
| Jun 10, 2022 | Freeman Mason Chief Medical Officer | Sale | 6 | $91 | Form 4 |
| Feb 24, 2023 | Freeman Mason Chief Medical Officer | Other | 100 | $3K | Form 4 |
| Feb 24, 2023 | Freeman Mason Chief Medical Officer | Other | 40,000 | — | Form 4 |
| Feb 24, 2023 | Kalb Michael Wayne EVP & Chief Financial Officer | Other | 202,437 | $5.26M⚡ | Form 4 |
| Feb 24, 2023 | Pearce Catherine COO | Other | 140,149 | $3.64M⚡ | Form 4 |
| Feb 24, 2023 | Pearce Catherine COO | Other | 1,500 | $39K | Form 4 |
| Feb 24, 2023 | Pearce Catherine COO | Other | 15,000 | — | Form 4 |
| Feb 24, 2023 | de Garidel Marc CEO · Director | Other | 12,500 | $325K | Form 4 |
| Feb 24, 2023 | de Garidel Marc CEO · Director | Other | 200,000 | — | Form 4 |
| Jan 26, 2023 | de Garidel Marc CEO · Director | Award | 200,000 | — | Form 4 |
| Jan 26, 2023 | Pearce Catherine COO | Award | 15,000 | — | Form 4 |
| Jan 26, 2023 | Kalb Michael Wayne EVP & Chief Financial Officer | Award | 177,000 | — | Form 4 |
| Jan 26, 2023 | Freeman Mason Chief Medical Officer | Award | 40,000 | — | Form 4 |
| Jan 11, 2023 | Pearce Catherine COO | Option | 13,235 | — | Form 4 |
| Jan 11, 2023 | Pearce Catherine COO | Other | 3,997 | $115K | Form 4 |
| Nov 4, 2022 | Kalb Michael Wayne EVP & Chief Financial Officer | Award | 25,437 | — | Form 4 |
| Aug 15, 2022 | 5AM Partners VI, LLC 10 percent owner | Purchase | 112,667 | $3.38M⚡ | Form 4 |
| Aug 15, 2022 | 5AM Partners VI, LLC 10 percent owner | Purchase | 487,333 | $14.62M⚡ | Form 4 |
| Aug 15, 2022 | 5AM Opportunities II, L.P. Director | Purchase | 487,333 | $14.62M⚡ | Form 4 |
5AM Partners VI, LLC
10 percent owner
日期
Feb 24
股数
496,323
均价
$26.00
总金额
$12.90M ⚡
Kalb Michael Wayne
EVP & Chief Financial Officer
日期
Feb 24
股数
202,437
均价
$26.00
总金额
$5.26M ⚡
5AM Partners VI, LLC
10 percent owner
日期
Aug 15
股数
112,667
均价
$30.00
总金额
$3.38M ⚡
5AM Partners VI, LLC
10 percent owner
日期
Aug 15
股数
487,333
均价
$30.00
总金额
$14.62M ⚡
5AM Opportunities II, L.P.
Director
日期
Aug 15
股数
487,333
均价
$30.00
总金额
$14.62M ⚡
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 CINC 内幕交易
CINC 内幕交易
CinCor Pharma, Inc.（CINC）内幕交易数据来源于公司内部人（包括CINC）提交的SEC Form 4申报文件。过去12个月内，0位内部人向SEC提交了交易申报。CINC内部人近期主要在买入，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看CinCor Pharma, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
CINC 内幕交易 · 5个问题CinCor Pharma, Inc.（CINC）的内部人包括高管和董事，如CINC等。过去12个月内，0位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026